The listing of Yuanxin Technology accelerated, and the revenue and gross profit were both ** The health of the business has been further improved
In recent years, China's aging population has intensified, and the demand for medical and health care has continued to be strong, based on the promotion of medical reform and national policy support, China's medical and health industry has ushered in a stage of rapid development. The representative brands of the industry, including Yuanxin Technology, have also shown a steady and upward development trend. According to the latest prospectus data released by Yuanxin Technology on December 18, 2023, in the first half of 2023, Yuanxin Technology's total revenue reached 464.5 billion, an increase of 431%, with a gross margin of 88%, maintaining steady growth over the same period.
Yuanxin Technology is a powerful group of medical and health enterprises in China, founded in 2015. Yuanxin Technology has always insisted on delivering value to patients, and in line with the corporate vision of "becoming the first choice of medical drugs for the people", its business has been divided into three major sectors: out-of-hospital patient services, supply-side empowerment services and medical industry-side empowerment services. Driven by the combined advantages of the three business segments and the medical insights accumulated by the brand, Yuanxin Technology continues to improve the medical experience and effectiveness of patients, and has built a closed loop of "medical-pharmaceutical-insurance" ecological services, which can provide patients with comprehensive, personalized and considerate services.
In recent years, the three major business segments of Yuanxin Technology have not only maintained good development, but also become more and more synergistic. This is also reflected in the latest prospectus. According to the prospectus, as the early core business of Yuanxin Technology and an important business segment of Yuanxin Technology for the C-end, in the first half of 2023, the performance of out-of-hospital patient services continued to be stable, and as of June 30, 2023, the revenue of this segment reached 441.5 billion, a year-on-year increase of 418%。During the same period, Yuanxin Technology has 138 dual-channel pharmacies for serious illness medical insurance, and has formed a unique geographical location and "dual-channel" business advantages.
Compared with the out-of-hospital patient service business, in the first half of 2023, Yuanxin Technology's two major business segments for the B-side, namely: supply-side empowerment services and medical industry-side empowerment services, achieved more obvious performance**. The prospectus discloses: As of June 30, 2023, the revenue of Yuanxin Technology's supply-side empowerment services increased by 789%, and the gross margin increased to 522%；The revenue of the medical industry end-side empowerment service increased by 74% year-on-year3%, and the gross margin increased to 514%。Both segments have achieved rapid growth and are growing even faster. This also means that the main revenue of Yuanxin Technology has shifted from out-of-hospital patient services to supply-side empowerment services and medical industry empowerment services.
According to Frost & Sullivan, in 2022, Yuanxin Technology has become China's largest offline and online medical delivery platform focusing on prescription drugs in terms of revenue. Through the new prospectus, it can be seen that Yuanxin Technology presents a healthier revenue model and a good revenue structure, which will increase the listing of Yuanxin Technology, help enhance the market competitiveness of Yuanxin Technology, and add wings to the future development of the company.